Cargando…

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Roeker, Lindsey E., Knorr, David A., Pessin, Melissa S., Ramanathan, Lakshmi V., Thompson, Meghan C., Leslie, Lori A., Zelenetz, Andrew D., Mato, Anthony R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450257/ https://www.ncbi.nlm.nih.gov/pubmed/32855439 http://dx.doi.org/10.1038/s41375-020-01030-2

Ejemplares similares

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021)

Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions
por: Mato, Anthony R., et al.
Publicado: (2022)

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2021)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

A History of Targeted Therapy Development and Progress in Novel–Novel Combinations for Chronic Lymphocytic Leukemia (CLL)
por: Karr, Matthew, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
por: Rossi, Davide, et al.
Publicado: (2020)

Data to support a simultaneous testosterone and estradiol assay in serum by LC-MS/MS
por: Schofield, Ryan C., et al.
Publicado: (2018)

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
por: Mato, Anthony R., et al.
Publicado: (2018)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic
por: Arellano-Llamas, Abril Adriana, et al.
Publicado: (2022)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
por: Mato, Anthony, et al.
Publicado: (2023)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant in Patients With Chronic Lymphocytic Leukemia: Case Series
por: Khamees, Ibrahim, et al.
Publicado: (2022)

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2022)

Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic
por: Mihaila, Romeo Gabriel
Publicado: (2021)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
por: Rhodes, Joanna M, et al.
Publicado: (2021)

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022)

Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies
por: Seganfredo, Fernanda Braga, et al.
Publicado: (2022)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte‐binding anti‐CD antibody microarray
por: Khvastunova, Alina N., et al.
Publicado: (2018)

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
por: Lansigan, Frederick, et al.
Publicado: (2023)

CLL-370: The Prolonged Positivity of SARS-CoV-2 RNA in Chronic Lymphocytic Leukemia Patients
por: Popov, Viola, et al.
Publicado: (2020)

Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey
por: Leung, Leslie Y. T., et al.
Publicado: (2021)

CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022)

Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Poster: CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Mellinghoff, Sibylle C., et al.
Publicado: (2021)

Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE
por: Reynolds, John A, et al.
Publicado: (2023)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
por: Emond, Bruno, et al.
Publicado: (2019)

The Use of Monoclonal Antibodies in the Treatment of Autoimmune Complications of Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2013)

A cross‐sectional community‐based observational study of asymptomatic SARS‐CoV‐2 prevalence in the greater Indianapolis area
por: Meyers, Kristin J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_edc06o6ba3jt1nvm960uokt19v